The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck; Novartis
Research Funding - Bayer; Lilly; Novartis
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Juan W. Valle
Consulting or Advisory Role - Agios; AstraZeneca; Baxalta; Delcath Systems; Ipsen; Lilly; Merck; Midatech Pharma; Novartis; Pfizer
Speakers' Bureau - Celgene; Novartis; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Lilly; Novartis
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst)
 
Lipika Goyal
Honoraria - Ribon Therapeutics
Research Funding - Dicerna; Exelixis; Leap Therapeutics; Taiho Pharmaceutical
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme
Research Funding - Agios; Celgene; Lilly
Travel, Accommodations, Expenses - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme
 
Milind M. Javle
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun BioPharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
James M. Cleary
Honoraria - Agios
Research Funding - Merck
Travel, Accommodations, Expenses - Agios; Roche
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CytomX Therapeutics
Speakers' Bureau - Merrimack
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Teresa Mercade Macarulla
No Relationships to Disclose
 
Arndt Vogel
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Delcath Systems; Lilly; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Baxalta; Bayer; Delcath Systems; Lilly; Novartis; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Christopher Korth
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Liewen Jiang
Employment - Agios
Stock and Other Ownership Interests - Alexion Pharmaceuticals
 
Camelia Gliser
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Bin Wu
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios
 
Samuel V. Agresta
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios
 
Shuchi Sumant Pandya
Employment - Acceleron Pharma; Agios
Stock and Other Ownership Interests - Acceleron Pharma; Agios
Research Funding - Acceleron Pharma; Agios
 
Andrew X. Zhu
No Relationships to Disclose